Adaptive Biotechnologies announced Monday that it plans to split its immune medicine operation away from its cancer-testing division, as the company weighs what to do with its drug-discovery business and doubles down on diagnostic testing.
The company said it is currently exploring all available options for the immune medicine platform and expects to settle on a preferred course of action by the close of 2026.
Adaptive’s immune medicine platform is designed to assist in drug research by pinpointing therapeutic targets and speeding up the development of precision-based treatments.
Meanwhile, the company’s cancer-testing division — which includes its clonoSEQ diagnostic test — has turned a profit and expanded its coverage through insurance providers, the company said.
The clonoSEQ test is used to detect tiny amounts of cancer that may still be present in a patient’s body following treatment, and it is also utilized in drug-development research studies.
Revenue from the cancer-testing unit climbed to $212 million in 2025, up significantly from $103 million in 2023, according to the company.
Adaptive indicated that the immune medicine business may be a better fit outside of the company’s diagnostics-centered structure.
The company cautioned that there is no guarantee the review process will lead to a transaction or any specific result.
